Under the agreement, the companies will create a workflow integrating NanoString's GeoMx Digital Spatial Profiling instrument with Leica's Bond RX autostainer.
Under the agreement, Abcam will create custom panels for NanoString's GeoMx DSP platform from its collection of 6,000-plus recombinant monoclonal antibodies.
The planned product would combine RNA assays for NanoString's GeoMx digital spatial profiling instrument with Bio-Techne's RNAscope imaging reagents.
The company said it will offer 4.5 million shares for $23 per share and intends to use the net proceeds for working capital and general corporate purposes.
The company said it will offer 2.5 million shares, while stockholder Clarus Lifesciences will sell another 2 million shares in the offering.
Though the firm saw lower overall revenue, it increased its fourth quarter and full-year product and services revenue by 12 percent and 16 percent respectively.
Researchers are turning to spatial technologies to study tumor heterogeneity and as a complement to single-cell sequencing to locate specific cell types.
The index, which outperformed the Dow Jones and the Nasdaq this month, gained 11 percent and rebounded from its 11 percent loss in December.
In PLOS this week: statistical approach for integrating eQTL and GWAS data, microRNA signature distinguishes malignant and benign salivary gland tumors, and more.
CEO Brad Gray told investors at the JP Morgan Healthcare Conference that he believes the firm's GeoMx has advantages over competitors in the new market.
The New York Times Magazine examines gender discrimination at the Salk Institute.
Science reports that MD Anderson Cancer Center has dismissed three researchers over foreign tie concerns.
A second death in gene therapy trial for type 1 spinal muscular atrophy is under investigation, according to Reuters.
In PLOS this week: antibiotic resistance patterns in Escherichia coli, a dozen genetic loci tied to varicose vein risk, and more.